The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine-Reference-Cited by-同舟云学术

The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine

Published:2015-12-23 Issue:8 Volume:22 Page:1958-1968
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Miltiades Paraskevi,Lamprianidou Eleftheria,Vassilakopoulos Theodoros P.,Papageorgiou Sotirios G.,Galanopoulos Athanasios G.,Kontos Christos K.,Adamopoulos Panagiotis G.,Nakou Evangelia,Vakalopoulou Sofia,Garypidou Vassilia,Papaioannou Maria,Hatjiharissi Evdoxia,Papadaki Helen A.,Spanoudakis Emmanuil,Pappa Vassiliki,Scorilas Andreas,Tsatalas Constantinos,Kotsianidis Ioannis

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia;Experimental Hematology & Oncology;2022-03-02

2. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine;Epigenomics;2021-07

3. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?;Leukemia Research;2021-04

4. Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter;Frontiers in Oncology;2021-03-09

5. Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome;Annals of Hematology;2021-01-09